Skip to main content

Volume 11 Supplement 1

Challenges in malaria research

Chemotherapeutics for vivax malaria

Plasmodium vivax imposes significant burdens of morbidity and mortality across the malaria endemic world. Treatment of this infection requires a blood schizontocide against the acute attack and hypnozoitocide against relapses. Chloroquine combined with primaquine has been the therapy of choice for radical cure of vivax malaria since the 1950s. Primaquine, however, was never optimized or adapted for use in endemic zones and its toxicity in prevalent G6PD-defkient patients (typically 5-20%) sharply limits its effectiveness. Resistance to chloroquine has emerged in Southeast Asia and now threatens the Indian sub-continent where most P. vivax occurs. The research community faces the steep challenge of developing new radical cure strategies. This presentation explores those challenges and the means to meet them, principally optimizing primaquine as a partner to new ACTs for maximum efficacy and more practical dosing and safety.

Author information

Affiliations

Authors

Corresponding author

Correspondence to J Kevin Baird.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Baird, J.K. Chemotherapeutics for vivax malaria. Malar J 11, O21 (2012). https://doi.org/10.1186/1475-2875-11-S1-O21

Download citation

Keywords

  • Infectious Disease
  • Malaria
  • Plasmodium
  • Research Community
  • Chloroquine
\